Journal: Cellular oncology (Dordrecht)

Article Title: Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

doi: 10.1007/s13402-016-0297-1

Figure Lengend Snippet: A snapshot of therapeutic approaches aiming at leukemic stem cells that are available for the management of hematological malignancies

Article Snippet: This table provides a snapshot of the treatment modalities that may target LSCs and that are available for the (pre)clinical management of hematologic malignancies. table ft1 table-wrap mode="anchored" t5 caption a7 Target Compound References Cell surface antigens Gemtuzumab, DT 388 IL3, 7G3 antibody, H90 antibody, Dacluzumab, B6H12.2 or BRIC 126, 21.16 and 1075.7, αCLL1-αCD3, 81.2 antibody [ 13 , 27 , 33 , 39 , 40 , 44 – 46 , 160 ] Differentiation therapies ATRA, DFO, DFX, EP, Sabutoclax [ 48 , 53 , 54 ] Mitochondria and metabolic pathways Sabutoclax, MEK inhibitor with ABT-737, obutoclax with sorafenib, tigecycline, PKM2 [ 59 – 63 , 66 , 67 ] Epigenetic regulators VAL-AZA, DOT1L, LSD1, EZH2, IDH1/2, Menin, Brd4, menin-MLL inhibitors, LSD1 inhibitors, DZNep [ 73 – 78 , 80 – 82 , 161 ] Cell signaling pathways PTL, DMAPT, Celastrol, 4-HNE, AR42, AS602869, LY29402, VP16, Wortmannin, Perifosine, Sirolimus, etoposide, clofarabine, NVP-BEZ235, GDC-0980, XL-765 [ 86 , 90 , 92 , 94 , 98 , 99 , 102 , 105 , 106 , 110 – 112 ] Reactive oxigen species PTL, piperolongumine, DZNep, AF, Fenretinide, Deferaxirox [ 53 , 82 , 90 , 117 , 119 ] Heat shock proteins 17-AAG, 17-DMAG, PU-H71 [ 124 – 127 ] Self renewal pathways Hydrazones, Homoharringtonine, AV65, Indometacin, GSI, cyclopamine [ 9 , 137 , 138 , 140 , 142 ] Microenvironment disruptions Perixafor, neutralizing CXCR4 or CXCL12 antibodies, AMD3465, echinomycin, E-selectin ligand [ 5 , 149 – 151 ] Open in a separate window A snapshot of therapeutic approaches aiming at leukemic stem cells that are available for the management of hematological malignancies 4.8 CML and tyrosine kinase inhibitors As outlined above, tyrosine kinase inhibitors (TKIs) represent a group of small molecules that can specifically block the kinase activities of its target proteins.

Techniques: